The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.
Their finding is the first to link individual differences written into the genetic code with a vaccine-related complication, albeit a mild one.
The study, published in the July 15th issue of The Journal of Infectious Diseases, now available online, may have implications for predicting adverse events from other live vaccines. .
The use of computers to advance human disease research - known as bioinformatics -- has received a major boost from researchers at the La Jolla Institute for Allergy & Immunology (LIAI).
Scientists working with Vaccinia virus, the smallpox vaccine, have discovered a novel mechanism that allows poxviruses to enter cells and cause infection.
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have identified a defect in the immune response of people with the skin condition atopic dermatitis that puts them at risk of developing serious complications following smallpox vaccination.
Smallpox is considered a potential terrorist weapon, but millions of people in the United States are currently advised not to get a vaccine to the disease because they are susceptible to developing a severe adverse reaction.
Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.
Mice given a relatively new cancer drug can survive an otherwise lethal dose of vaccinia virus, a relative of smallpox virus, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID).
Vaccine strategies are being designed to battle cancer, but their use for metastatic melanoma is a challenge.
Interim data from a phase I/II clinical trial of a next-generation vaccine for smallpox suggest that the vaccine may provide immunity and thus far the trial has been without any serious adverse events.
The U.S. Food and Drug Administration (FDA) has approved Vaccinia Immune Globulin Intravenous (VIGIV) - the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.
United States Department of Health and Human Services has announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), will administer the contracts.
A team of scientists led by a Howard Hughes Medical Institute (HHMI) international research scholar has discovered the immune system mechanism that causes some mice to be more susceptible to mousepox than others.
A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.
When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a five-year, $20.7 million grant to National Jewish Medical and Research Center to lead a consortium of academic medical centers trying to make smallpox vaccines safer for millions of people with atopic dermatitis, also known as eczema.
Not everybody can safely be vaccinated against smallpox using the current FDA-approved vaccine. Scientists hope another study vaccine, now undergoing its first testing in the United States at Saint Louis University, will give a choice to people who can't be given the current vaccine, known as Dryvax®.
In the first successful study of its kind, scientists have shown that a DNA-based vaccine for smallpox can protect nonhuman primates from monkeypox, a disease that resembles smallpox in humans.
Scientists at the University of Illinois at Urbana-Champaign studying vaccinia virus, a close relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation, a crucial anti-viral immune response of host cells.